HOME >> BIOLOGY >> NEWS
Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Hawthorne, NY June 28, 2002 Acorda Therapeutics announced today that it has begun two Phase 3 clinical studies of its lead product, Fampridine-SR, in chronic spinal cord injury. The trials will evaluate the safety and efficacy of Fampridine-SR in the treatment of moderate-to-severe spasticity associated with chronic SCI. Spasticity, which affects up to 75% of people with chronic SCI, manifests itself as involuntary stiffness or contraction of muscles.

The studies will enroll a total of 360 patients at more than 70 of the leading spinal cord injury (SCI) clinical centers in the United States and Canada. Individuals who are interested in finding out about participating in these studies may call 866-206-2322, toll-free, weekdays from 9:00 a.m. (EDT) to 7:00p.m. (EDT)

"There is significant demand for new treatment options in chronic spinal cord injury, especially spasticity. Spasticity is a serious complication of SCI that frequently interferes with movement and daily activities, and can cause severe pain or injury," said Ron Cohen, MD, Acorda's President and Chief Executive Officer.

Fampridine ("4-aminopyridine", "4-AP") enhances conduction in damaged nerves, and is the first compound shown to restore some neurological function to people with SCI. Fampridine-SR is an oral, sustained-release formulation of fampridine, designed for twice-daily dosing. The drug restores nerve conduction by blocking exposed potassium channels in demyelinated nerve processes, or axons. Fampridine-SR is also in Phase 2 clinical trials to evaluate safety and efficacy in the treatment of symptoms associated with multiple sclerosis (MS).

In previous SCI clinical trials, administration of Fampridine-SR has been shown to reduce spasticity, and to improve sexual function and bowel and bladder control. The most common side effects observed with Fampridine-SR treatment have been pain, paresthesia, insomnia, dizziness, constipation, and nausea. At clin
'"/>


1-Jul-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: